TITLE

Long-term trends in use of and expenditures for cardiovascular medications in Canada

AUTHOR(S)
Jackevicius, Cynthia A.; Cox, Jafna L.; Carreon, Daniel; Tu, Jack V.; Rinfret, Stéphane; So, Derek; Johansen, Helen; Kalavrouziotis, Dimitri; Demers, Virginie; Humphries, Karin; Pilote, Louise
PUB. DATE
July 2009
SOURCE
CMAJ: Canadian Medical Association Journal;7/7/2009, Vol. 181 Issue 1/2, pE19
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Medication expenditures have become the fastest growing sector of costs within the Canadian health care system. Evaluation of the use of cardiovascular medications is important to determine the magnitude of the growth, to identify which medications dominate the landscape and to detect interprovincial differences in utilization. We describe long-term trends in the use of and expenditures for cardiovascular medications in Canada, by drug class and by province. Methods: For these analyses, we used volume and expenditure data related to prescriptions for cardiovascular medications obtained from IMS Health Canada's Compu Script Audit ® database for the period 1996-2006. Here, we describe national and provincial patterns of utilization and expenditures for specified classes of cardiovascular medications. Results: The use of cardiovascular medications increased sharply in Canada during the study period, with related costs rising by over 200% during this period to surpass $5 billion in 2006. Changes in population demographics, risk factors and inflation appeared to account for about two-thirds of the observed growth in expenditures. Use of newer medication classes (statins, angiotensin-receptor blockers, angiotensin-converting-enzyme inhibitors), for which patented brand name medications predominate, accounted for almost one-third of the cost increases. Interprovincial differences in total expenditures for cardiovascular drugs portrayed a descending gradient from east to west, with greatest variability for the newer drug classes. Interpretation: Prescriptions and expenditures for cardiovascular medications in Canada escalated over the study period. Projected increases may reach potentially unsustainable levels. Greater emphasis on the use of cost- effective medications is required to limit further increases. Factors influencing interprovincial differences warrant further study.
ACCESSION #
42749799

 

Related Articles

  • Should a statin be routinely prescribed for primary prevention of cardiovascular disease in diabetes mellitus? Hackam, Daniel G. // CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p857 

    Presents a study on the use of statins in preventing cardiovascular disease (CVD) in patients with type 2 diabetes. Procedures of the study; Factors that should be considered by clinicians for those without CVD; Effects of statins on the patients.

  • Should we use statins for primary prevention of cardiovascular disease? Kuriacose, Josef // Pulse;10/6/2010, Vol. 70 Issue 29, p16 

    The article offers views and insights from medical experts regarding the effectiveness of statins for cardiovascular disease treatment. George Kassianos emphasized that the enzyme inhibitors would give 90% efficacy to lower down cholesterol levels to patients with active myocardial infarction,...

  • Cost of Heart Drugs Makes Patients Skip Pills, Putting Themselves at Risk.  // Biomedical Market Newsletter;4/30/2011, p76 

    The article reports on the study that evaluates the health risk of patients who failed to take medication due to the cost of heart drugs in Minnesota. As stated, younger patients more likely skip the intake of heart medications than older patients with financial concern as the main reason of 46...

  • Patients fail to take statins correctly. Pedder, Cato // Pulse;1/19/2004, Vol. 64 Issue 3, p7 

    Reports on the re-emergence of statins in medical research in Great Britain. Research on compliance, combined therapy and pharmacy-based cholesterol screening; Percentage of failures committed by patients in taking statins correctly; Importance of taking statins regularly.

  • statins.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2197 

    A definition of the term "statins," which refers to any of the drugs from the class known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, is presented.

  • Use of n-of-1 trials to determine statin tolerability.  // Reactions Weekly;Apr2014, Vol. 1495 Issue 1, p4 

    The article presents the findings of a recent study that confirmed the feasibility and potential value of n-of-1 trials in providing a reliable means of assessing whether such symptoms are in fact attributable to the statin.

  • JUPITER data could expand number of older U.S. adults who may benefit from statin therapy. Kalvaitis, Katie // Cardiology Today;Mar2009, Vol. 12 Issue 3, p25 

    The article discusses a study published in volume 2 of "Circulation: Cardiovascular Quality and Outcomes" which suggested that more than 11 million older people in the U.S. may be eligible for statin therapy, based on results of the Justification for the Use of Statins in Primary Prevention: an...

  • Guidelines for Cardiovascular Risk Assessment and Cholesterol Treatment. Ioannidis, John P. A. // JAMA: Journal of the American Medical Association;6/4/2014, Vol. 311 Issue 21, p2235 

    A response by the author of the article "More Than a Billion People Taking Statins? Potential Implications of the New Cardiovascular Guidelines" in the 2014 issue is presented.

  • Nitridergic Modulation of the Antinociceptive Activity of Rosuvastatin in Mice. Noriega, Viviana; Sierralta, Fernando; Prieto, Juan Carlos; Zanetta, Pilar; Miranda, Hugo F. // Pharmacology & Pharmacy;Jan2014, Vol. 5 Issue 1, p61 

    Statins, 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase enzyme inhibitors, are lipid-lowering drugs, often used in the treatment of cardiovascular diseases (hyperlipidemia, atherosclerosis). It has been shown that statins have antiinflammatory effects independent of their...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics